Amalgam Rx is a Wilmington, Delaware–based digital health company whose core offering is a modular software-as-a-medical-device (SaMD) platform integrated with EHR solutions and powered by medical-grade artificial intelligence. The platform partners with life-science companies, health plans, and providers to embed AI-driven decision support directly into clinical workflows and patient experiences. According to the company, its solutions currently support nearly 10 million patients across four continents and have generated more than 70 million clinical decisions. Amalgam Rx states that the technology empowers both patients in their daily disease management and clinicians in evidence-based care delivery. With fresh capital, the company plans to further scale its AI capabilities and expand deployment of its tools. No revenue figures were disclosed, but the new financing adds to the firm’s resources for growth and product development.

Total raised

$37M

Funding rounds

3

Latest round

Debt Financing

Latest activity

Aug 2025